Developer docs
API playgroundTry for free, no card

Search company profiles

Nordic Bioproducts Group

Full company profile

uuid0023fmc

Namestring
Nordic Bioproducts Group
Legal namestring
Nordic Bioproducts Group Oy
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Nordic Bioproducts Group Oy is a Finnish biomaterials company founded in 2019 as a spin-off from Aalto University by Professor Olli Dahl and Olli Kähkönen. The company develops and commercializes its patented AaltoCell™ continuous-flow process for hydrolyzing lignocellulosic materials into high-purity microcrystalline cellulose (MCC) and cellulose derivatives. AaltoCell is positioned as the world's first commercial continuous MCC production process, claiming up to 81% lower carbon footprint, 95% lower water use, 90% lower energy use, and 69% fewer chemicals versus conventional batch production methods.

The company sells the PURA Series™ family of MCC products — Super Flow (spherical granules for pharma/nutraceuticals), Universal Premium (standard powders), Nordic Beauty (cosmetic ingredients replacing PMMA, nylon, TiO2 and microplastics), and MCC Spheres (pre-commercial microplastic alternative) — together with the Norratex™ technology for sustainable wood-based textile fibers. Production takes place at the EXCiPACT® and ISO 9001:2015-certified Lappeenranta facility with up to 10,000 tons annual capacity (opened April 2024); R&D is conducted at the B.I.G. (Bio Innovation Garage) facility on Aalto University's Otaniemi campus in Espoo.

Nordic Bioproducts Group generates revenue through direct MCC product sales to pharmaceutical, nutraceutical, food, cosmetics, and bioplastic manufacturers, supplemented by licensing of the AaltoCell™ platform to industrial partners (Marubeni in Indonesia, PTT MCC in Thailand) and contract R&D services through B.I.G. Distribution to international customers is conducted both directly and via a Hamburg-based channel partnership with ACT Group signed in February 2026. The company is privately held, with a 20% strategic minority stake held by Japan's Oji Holdings Corporation since January 2026.

Short descriptiontext

Nordic Bioproducts Group is a Finnish biomaterials company that produces sustainable microcrystalline cellulose (MCC) via its patented AaltoCell™ continuous-flow process, selling PURA Series™ ingredients to pharmaceutical, nutraceutical, food, cosmetics, and bioplastic manufacturers from its Lappeenranta facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEspoo, Finland
HQ citystring
Espoo
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
microcrystalline cellulose, cellulose excipients, biomaterials production, pharmaceutical excipients, cellulosic materials
Industry5 codes
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYIMAEAOAG
Biodegradable Fibers & Nonwovens (industrial textiles, wipes)
SECONDARYIMAMALAK
Bio-based Textiles & Fibers (lyocell/viscose, cellulose filament, nonwovens)
SECONDARYEUAAAIAD
Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYIMAEAOAE
Cellulose-Based Biodegradable Materials (cellulose films, fibers, derivatives)
NAICS code3 codes
  • Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing3252
  • Nonwoven Fabric Mills31323
  • Textile Product Mills314
SIC code3 codes
  • Plastic Material, Synth Resin/Rubber, Cellulos (No Glass)2820
  • Industrial Organic Chemicals2860
  • Broadwoven Fabric Mills, Man Made Fiber & Silk2221
Product category
Specialty Cellulose Excipients
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1MCC and Cellulose Product Sales
TypeOne Time License
Description

Sale of proprietary PURA Series™ MCC products — Super Flow, Universal Premium, Nordic Beauty, and MCC Spheres — to pharmaceutical, nutraceutical, food, cosmetics, and personal care manufacturers. Revenue from direct product sales with pricing based on volume and specifications. The facility can produce up to 10,000 tons annually.

nordicbioproducts.fi
2Technology Licensing
TypeLicensing Royalties
Description

Licensing of AaltoCell™ technology platform to industrial partners for deployment in their own facilities. Includes licensing for MCC production and broader biorefinery applications. Partners include Marubeni (Indonesia) and PTT MCC (Thailand).

nordicbioproducts.fi
3R&D and Contract Development Services (BIG)
TypeProfessional Services
Description

R&D services through the Bio Innovation Garage (B.I.G.), offering joint development projects with partners and customers. Includes contract research, feasibility studies, and custom cellulose solution development for industrial clients.

nordicbioproducts.fi
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1AaltoCell
Description

Patented technology platform for producing high-value microcrystalline cellulose (MCC) and cellulose derivatives with significantly reduced environmental impact

nordicbioproducts.fi
+7 more records
Core offering1 text field

Nordic Bioproducts Group manufactures and sells high-purity microcrystalline cellulose (MCC) products under its PURA Series™ brand, produced via its patented AaltoCell™ continuous-flow process. The portfolio includes PURA Series Super Flow (spherical granules for pharma/nutraceuticals), Universal Premium (market-standard MCC powders), Nordic Beauty (cosmetic-grade MCC), and MCC Spheres (microplastic replacements). The company also develops the Norratex™ technology for sustainable textile fibers and operates the B.I.G. (Bio Innovation Garage) R&D facility.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 81% lower carbon footprint (434.6 kg CO2e per ton MCC) vs conventional methods
+7 more records
Product overview1 text field

Nordic Bioproducts Group operates a platform-based business centered on its patented AaltoCell™ continuous production technology for manufacturing microcrystalline cellulose (MCC) and cellulose derivatives from forest biomass. The company produces the PURA Series™ product family including Super Flow granules (spherical particles for pharmaceuticals/nutraceuticals), Universal Premium powders, Nordic Beauty ingredients for cosmetics, and MCC Spheres as microplastic replacement. Supporting technologies include Norratex™ for sustainable textile fibers. The company operates the B.I.G. (Bio Innovation Garage) R&D facility in Espoo and a commercial-scale EXCiPACT-certified production facility in Lappeenranta, Finland with capacity up to 10,000 tons annually.

Product and service5 records
1PURA Series™ Super Flow MCC
CategoryPharmaceutical Excipients
Description

High-purity microcrystalline cellulose granules with unique spherical morphology offering exceptional flowability and consistent performance for pharmaceutical, nutraceutical, personal care, and cosmetics applications. Available in Super Flow 75, 150, and 450 grades; complies with Ph. Eur., USP/NF, JP standards.

2PURA Series™ Universal Premium MCC
CategoryPharmaceutical Excipients
Description

Market-standard MCC powders functioning as texturing agents, anti-caking agents, stabilizers, and binders across pharmaceuticals, nutraceuticals, and consumer products. Available in UP15, UP65, and UP95 grades.

3PURA Series™ Nordic Beauty MCC
CategoryCosmetic Ingredients
Description

100% biobased, fossil-free, biodegradable MCC ingredient range for modern cosmetic formulations. Available as Powders (15) and Pearls (75, 150, 450) replacing synthetic alternatives.

4PURA Series™ MCC Spheres
CategoryCosmetic Ingredients
Description

Fully cellulose-based perfectly spherical particles in customizable sizes offering microplastic replacement for cosmetics with 100% cellulose composition, low nitrite levels, reduced carbon footprint, and full compostability.

5Norratex™ Textile Fiber Technology
CategorySustainable Textile Technology
Description

Novel process for producing sustainable wood-based textile fibers from pulp feedstock. Carbon disulfide free with minimal commonly used chemicals that are easily recovered, designed as a drop-in solution for pulp mills.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-17
Description

Strategic distribution partnership signed February 2026 with ACT Group, a Hamburg-based trading company with 40+ years of experience in international distribution of raw materials and functional ingredients. ACT provides NBG with access to its customer network of nutraceutical, pharmaceutical, personal care, food, and industrial manufacturers, plus technical sales, regulatory expertise, and logistics infrastructure.

Strategic tierMinorTypeOthersAnnounced on2024-06-26
Description

ACT is the EXCiPACT-accredited certification body that conducted the comprehensive audit and issued Nordic Bioproducts Group its EXCiPACT certification for pharmaceutical excipient production at the Lappeenranta facility.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-04-11
Description

MOU signed April 2024 for strategic collaboration to advance bioplastic innovation. NBG's activated cellulose fibers are used as ingredient in PTT MCC's BioPBS (bio-polybutylene succinate) product. Joint development project aims to create home-compostable bioplastics for single-use products such as coffee capsules, cutlery, and containers. Thailand is the world's second-largest bioplastics producer.

4Marubeni Corporation
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-25
Description

Comprehensive MOU signed January 2024 for long-term collaboration on sustainable biomass utilization. Partnership aims to establish a biorefinery in South Sumatra, Indonesia, processing kraft pulp and plantation residues (~290,000 hectares) using AaltoCell™ technology. Marubeni targets net-zero GHG emissions by 2050. Collaboration showcased at SusHi Tech Tokyo 2024.

nordicbioproducts.fi
5EV-Consulting and Fiber-X
Strategic tierMinorTypeOthersAnnounced on2022-01-01
Description

Built in collaboration with EV-Consulting and Fiber-X. The Lappeenranta production facility relies on 90% refurbished equipment.

nordicbioproducts.fi
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

FMC is a large-scale producer of microcrystalline cellulose and other pharmaceutical excipients. Competes with NBG across pharma and nutraceutical formulation applications and represents the type of established global supplier NBG must displace to gain share.

TypeBroad incumbent
Description

Borregaard is a Norwegian biorefinery company producing lignin, specialty cellulose derivatives, and bio-based vanillin from forest biomass. Shares NBG's Nordic forest-based feedstock model and broader biomaterials platform ambition, though Borregaard is far larger and more diversified.

TypeBroad incumbent
Description

Roquette is a global leader in starch-based and cellulosic excipients for pharma, food, and nutrition. While not an MCC pure-play, Roquette overlaps with NBG in pharmaceutical and nutraceutical excipient categories and represents the broader ingredient supplier competitive landscape.

TypeDirect peer
Description

Indian-headquartered Sigachi is a growing MCC manufacturer serving pharmaceutical, food, and personal care markets globally. Competes with NBG in price-sensitive segments and represents a similar scale and growth profile as a specialty MCC challenger.

5Asahi Kasei — Ceolus MCC
TypeDirect peer
Description

Asahi Kasei is one of the world's largest specialty MCC producers under the Ceolus brand, serving pharmaceutical and food applications globally. The company's scale, Japanese origin, and breadth of cellulose derivative grades position it as both a direct competitor and a benchmark for NBG's APAC ambitions.

6Sappi
TypeBroad incumbent
Description

South African-headquartered Sappi is a major dissolving pulp and biomaterials producer with growing interest in cellulose derivatives and sustainable textiles. Overlaps with NBG on feedstock (dissolving pulp), biorefining direction, and sustainable textile fiber ambitions (Norratex).

TypeDirect peer
Description

JRS Pharma is a major European manufacturer of cellulose-based pharmaceutical excipients including MCC grades (Vivapur). Shares NBG's European base and pharma excipient focus, making it the closest regional direct competitor in the formulation excipients market.

TypeDirect peer
Description

Taiwan-based Mingtai is a major Asian MCC producer serving pharmaceutical, food, and cosmetics customers globally. As a focused specialty MCC player with scale, Mingtai represents a direct comparable in product range and customer profile to Nordic Bioproducts Group.

TypeDirect peer
Description

DFE Pharma is a specialized excipient manufacturer with deep pharmaceutical customer relationships, producing MCC, lactose, and other functional excipients. Closely comparable to NBG in target customer base and product positioning within pharma formulation.

10DuPont (now IFF) — Avicel MCC
TypeDirect peer
Description

DuPont's Avicel brand is the historical market leader in pharmaceutical-grade microcrystalline cellulose. Operates at massive global scale with deeply entrenched pharma customer relationships, making it the most direct competitive benchmark for Nordic Bioproducts Group's PURA Series.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nordic Bioproducts Group

Specialty Cellulose Excipientsnordicbioproducts.fi

Nordic Bioproducts Group is a Finnish biomaterials company that produces sustainable microcrystalline cellulose (MCC) via its patented AaltoCell™ continuous-flow process, selling PURA Series™ ingredients to pharmaceutical, nutraceutical, food, cosmetics, and bioplastic manufacturers from its Lappeenranta facility.

What Nordic Bioproducts Group does

Nordic Bioproducts Group Oy is a Finnish biomaterials company founded in 2019 as a spin-off from Aalto University by Professor Olli Dahl and Olli Kähkönen. The company develops and commercializes its patented AaltoCell™ continuous-flow process for hydrolyzing lignocellulosic materials into high-purity microcrystalline cellulose (MCC) and cellulose derivatives. AaltoCell is positioned as the world's first commercial continuous MCC production process, claiming up to 81% lower carbon footprint, 95% lower water use, 90% lower energy use, and 69% fewer chemicals versus conventional batch production methods.

The company sells the PURA Series™ family of MCC products — Super Flow (spherical granules for pharma/nutraceuticals), Universal Premium (standard powders), Nordic Beauty (cosmetic ingredients replacing PMMA, nylon, TiO2 and microplastics), and MCC Spheres (pre-commercial microplastic alternative) — together with the Norratex™ technology for sustainable wood-based textile fibers. Production takes place at the EXCiPACT® and ISO 9001:2015-certified Lappeenranta facility with up to 10,000 tons annual capacity (opened April 2024); R&D is conducted at the B.I.G. (Bio Innovation Garage) facility on Aalto University's Otaniemi campus in Espoo.

Nordic Bioproducts Group generates revenue through direct MCC product sales to pharmaceutical, nutraceutical, food, cosmetics, and bioplastic manufacturers, supplemented by licensing of the AaltoCell™ platform to industrial partners (Marubeni in Indonesia, PTT MCC in Thailand) and contract R&D services through B.I.G. Distribution to international customers is conducted both directly and via a Hamburg-based channel partnership with ACT Group signed in February 2026. The company is privately held, with a 20% strategic minority stake held by Japan's Oji Holdings Corporation since January 2026.

Nordic Bioproducts Group firmographics

Firmographics
Name
Nordic Bioproducts Group
Legal name
Nordic Bioproducts Group Oy
Website
https://nordicbioproducts.fi
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Nordic Bioproducts Group is a Finnish biomaterials company that produces sustainable microcrystalline cellulose (MCC) via its patented AaltoCell™ continuous-flow process, selling PURA Series™ ingredients to pharmaceutical, nutraceutical, food, cosmetics, and bioplastic manufacturers from its Lappeenranta facility.
Ownership category
akta.pro rank

Nordic Bioproducts Group industry classification

Industry
Product category
Specialty Cellulose Excipients
NAICS
Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252), Nonwoven Fabric Mills (31323), Textile Product Mills (314)
SIC
Plastic Material, Synth Resin/Rubber, Cellulos (No Glass) (2820), Industrial Organic Chemicals (2860), Broadwoven Fabric Mills, Man Made Fiber & Silk (2221)
akta.pro industry
PRIMARYIMAMALAD
Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters)
SECONDARYIMAEAOAG
Biodegradable Fibers & Nonwovens (industrial textiles, wipes)
SECONDARYIMAMALAK
Bio-based Textiles & Fibers (lyocell/viscose, cellulose filament, nonwovens)
SECONDARYEUAAAIAD
Bio-based Materials & Fibers (e.g., cellulose derivatives, lignin-based materials, nanocellulose)
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
SECONDARYIMAEAOAE
Cellulose-Based Biodegradable Materials (cellulose films, fibers, derivatives)

Keywords

  • Microcrystalline cellulose
  • Cellulose excipients
  • Biomaterials production
  • Pharmaceutical excipients
  • Cellulosic materials

Where Nordic Bioproducts Group is headquartered

Location

Headquarters

HQ city
Espoo
HQ country
Finland
HQ region
Europe

Offices2 records

Markets served

Nordic Bioproducts Group business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Infrastructure

Revenue model

  1. MCC and Cellulose Product Sales: Sale of proprietary PURA Series™ MCC products — Super Flow, Universal Premium, Nordic Beauty, and MCC Spheres — to pharmaceutical, nutraceutical, food, cosmetics, and personal care manufacturers. Revenue from direct product sales with pricing based on volume and specifications. The facility can produce up to 10,000 tons annually.
  2. Technology Licensing: Licensing of AaltoCell™ technology platform to industrial partners for deployment in their own facilities. Includes licensing for MCC production and broader biorefinery applications. Partners include Marubeni (Indonesia) and PTT MCC (Thailand).
  3. R&D and Contract Development Services (BIG): R&D services through the Bio Innovation Garage (B.I.G.), offering joint development projects with partners and customers. Includes contract research, feasibility studies, and custom cellulose solution development for industrial clients.

Go-to-market motion4 records

Distribution channels3 records

Marketing channels5 records

Nordic Bioproducts Group product offering

Product offering

Core offering

Nordic Bioproducts Group manufactures and sells high-purity microcrystalline cellulose (MCC) products under its PURA Series™ brand, produced via its patented AaltoCell™ continuous-flow process. The portfolio includes PURA Series Super Flow (spherical granules for pharma/nutraceuticals), Universal Premium (market-standard MCC powders), Nordic Beauty (cosmetic-grade MCC), and MCC Spheres (microplastic replacements). The company also develops the Norratex™ technology for sustainable textile fibers and operates the B.I.G. (Bio Innovation Garage) R&D facility.

Product overview

Nordic Bioproducts Group operates a platform-based business centered on its patented AaltoCell™ continuous production technology for manufacturing microcrystalline cellulose (MCC) and cellulose derivatives from forest biomass. The company produces the PURA Series™ product family including Super Flow granules (spherical particles for pharmaceuticals/nutraceuticals), Universal Premium powders, Nordic Beauty ingredients for cosmetics, and MCC Spheres as microplastic replacement. Supporting technologies include Norratex™ for sustainable textile fibers. The company operates the B.I.G. (Bio Innovation Garage) R&D facility in Espoo and a commercial-scale EXCiPACT-certified production facility in Lappeenranta, Finland with capacity up to 10,000 tons annually.

Differentiator

Problem solved

Functional benefit

Brands

  • AaltoCell: Patented technology platform for producing high-value microcrystalline cellulose (MCC) and cellulose derivatives with significantly reduced environmental impact
  • PURA Series
  • Norratex
  • B.I.G. (Bio Innovation Garage)
  • PURA Series Super Flow
  • PURA Series Universal Premium
  • PURA Series Nordic Beauty
  • PURA Series MCC Spheres

Products and services

  • PURA Series™ Super Flow MCC High-purity microcrystalline cellulose granules with unique spherical morphology offering exceptional flowability and consistent performance for pharmaceutical, nutraceutical, personal care, and cosmetics applications. Available in Super Flow 75, 150, and 450 grades; complies with Ph. Eur., USP/NF, JP standards.
  • PURA Series™ Universal Premium MCC Market-standard MCC powders functioning as texturing agents, anti-caking agents, stabilizers, and binders across pharmaceuticals, nutraceuticals, and consumer products. Available in UP15, UP65, and UP95 grades.
  • PURA Series™ Nordic Beauty MCC 100% biobased, fossil-free, biodegradable MCC ingredient range for modern cosmetic formulations. Available as Powders (15) and Pearls (75, 150, 450) replacing synthetic alternatives.
  • PURA Series™ MCC Spheres Fully cellulose-based perfectly spherical particles in customizable sizes offering microplastic replacement for cosmetics with 100% cellulose composition, low nitrite levels, reduced carbon footprint, and full compostability.
  • Norratex™ Textile Fiber Technology Novel process for producing sustainable wood-based textile fibers from pulp feedstock. Carbon disulfide free with minimal commonly used chemicals that are easily recovered, designed as a drop-in solution for pulp mills.

Quantifiable outcome

  • 81% lower carbon footprint (434.6 kg CO2e per ton MCC) vs conventional methods
  • +7 more outcomes

Companies that use Nordic Bioproducts Group

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Nordic Bioproducts Group technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Nordic Bioproducts Group partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core, minor and flagship.

  • ACT Group (Atlantic Chemicals Trading)coreChannel Partner/ Reseller/ Distributor · 17 February 2026Strategic distribution partnership signed February 2026 with ACT Group, a Hamburg-based trading company with 40+ years of experience in international distribution of raw materials and functional ingredients. ACT provides NBG with access to its customer network of nutraceutical, pharmaceutical, personal care, food, and industrial manufacturers, plus technical sales, regulatory expertise, and logistics infrastructure.
  • ACT (EXCiPACT Certification Body)minorOthers · 26 June 2024ACT is the EXCiPACT-accredited certification body that conducted the comprehensive audit and issued Nordic Bioproducts Group its EXCiPACT certification for pharmaceutical excipient production at the Lappeenranta facility.
  • PTT MCC Biochem Co. Ltd.coreStrategic or Co-development Partner · 11 April 2024MOU signed April 2024 for strategic collaboration to advance bioplastic innovation. NBG's activated cellulose fibers are used as ingredient in PTT MCC's BioPBS (bio-polybutylene succinate) product. Joint development project aims to create home-compostable bioplastics for single-use products such as coffee capsules, cutlery, and containers. Thailand is the world's second-largest bioplastics producer.
  • Marubeni CorporationflagshipStrategic or Co-development Partner · 25 January 2024Comprehensive MOU signed January 2024 for long-term collaboration on sustainable biomass utilization. Partnership aims to establish a biorefinery in South Sumatra, Indonesia, processing kraft pulp and plantation residues (~290,000 hectares) using AaltoCell™ technology. Marubeni targets net-zero GHG emissions by 2050. Collaboration showcased at SusHi Tech Tokyo 2024.
  • EV-Consulting and Fiber-XminorOthers · 1 January 2022Built in collaboration with EV-Consulting and Fiber-X. The Lappeenranta production facility relies on 90% refurbished equipment.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Nordic Bioproducts Group competitors and assessment

Company assessment

Direct peers

  • FMC Corporation: FMC is a large-scale producer of microcrystalline cellulose and other pharmaceutical excipients. Competes with NBG across pharma and nutraceutical formulation applications and represents the type of established global supplier NBG must displace to gain share.
  • Sigachi Industries: Indian-headquartered Sigachi is a growing MCC manufacturer serving pharmaceutical, food, and personal care markets globally. Competes with NBG in price-sensitive segments and represents a similar scale and growth profile as a specialty MCC challenger.
  • Asahi Kasei — Ceolus MCC: Asahi Kasei is one of the world's largest specialty MCC producers under the Ceolus brand, serving pharmaceutical and food applications globally. The company's scale, Japanese origin, and breadth of cellulose derivative grades position it as both a direct competitor and a benchmark for NBG's APAC ambitions.
  • JRS Pharma (J. Rettenmaier & Söhne): JRS Pharma is a major European manufacturer of cellulose-based pharmaceutical excipients including MCC grades (Vivapur). Shares NBG's European base and pharma excipient focus, making it the closest regional direct competitor in the formulation excipients market.
  • Mingtai Chemical: Taiwan-based Mingtai is a major Asian MCC producer serving pharmaceutical, food, and cosmetics customers globally. As a focused specialty MCC player with scale, Mingtai represents a direct comparable in product range and customer profile to Nordic Bioproducts Group.
  • DFE Pharma: DFE Pharma is a specialized excipient manufacturer with deep pharmaceutical customer relationships, producing MCC, lactose, and other functional excipients. Closely comparable to NBG in target customer base and product positioning within pharma formulation.
  • DuPont (now IFF) — Avicel MCC: DuPont's Avicel brand is the historical market leader in pharmaceutical-grade microcrystalline cellulose. Operates at massive global scale with deeply entrenched pharma customer relationships, making it the most direct competitive benchmark for Nordic Bioproducts Group's PURA Series.

Broad incumbents

  • Borregaard: Borregaard is a Norwegian biorefinery company producing lignin, specialty cellulose derivatives, and bio-based vanillin from forest biomass. Shares NBG's Nordic forest-based feedstock model and broader biomaterials platform ambition, though Borregaard is far larger and more diversified.
  • Roquette: Roquette is a global leader in starch-based and cellulosic excipients for pharma, food, and nutrition. While not an MCC pure-play, Roquette overlaps with NBG in pharmaceutical and nutraceutical excipient categories and represents the broader ingredient supplier competitive landscape.
  • Sappi: South African-headquartered Sappi is a major dissolving pulp and biomaterials producer with growing interest in cellulose derivatives and sustainable textiles. Overlaps with NBG on feedstock (dissolving pulp), biorefining direction, and sustainable textile fiber ambitions (Norratex).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Nordic Bioproducts Group social profiles

Digital presence

Nordic Bioproducts Group compliance and trust

Trust signal

Compliance2 records

Nordic Bioproducts Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nordic Bioproducts Group leadership team

Management profile

Number of profiles

Profiles6 records

Nordic Bioproducts Group funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nordic Bioproducts Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nordic Bioproducts Group

What does Nordic Bioproducts Group do?

Nordic Bioproducts Group manufactures and sells high-purity microcrystalline cellulose (MCC) products under its PURA Series™ brand, produced via its patented AaltoCell™ continuous-flow process. The portfolio includes PURA Series Super Flow (spherical granules for pharma/nutraceuticals), Universal Premium (market-standard MCC powders), Nordic Beauty (cosmetic-grade MCC), and MCC Spheres (microplastic replacements). The company also develops the Norratex™ technology for sustainable textile fibers and operates the B.I.G. (Bio Innovation Garage) R&D facility.

Is Nordic Bioproducts Group a public or private company?

Nordic Bioproducts Group is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nordic Bioproducts Group founded?

Nordic Bioproducts Group was founded in 2019. It employs 11 to 50 people.

Where is Nordic Bioproducts Group based?

Nordic Bioproducts Group is headquartered in Espoo, Finland, in the Europe region.

How does Nordic Bioproducts Group make money?

Three revenue lines are on record. MCC and Cellulose Product Sales are the primary driver. The others are technology Licensing and R&D and Contract Development Services (BIG).

Who are Nordic Bioproducts Group's main competitors?

Direct peers on record are FMC Corporation, Sigachi Industries, Asahi Kasei — Ceolus MCC, JRS Pharma (J. Rettenmaier & Söhne), Mingtai Chemical, DFE Pharma and DuPont (now IFF) — Avicel MCC. Broad incumbents are Borregaard, Roquette and Sappi.

Does Nordic Bioproducts Group have an API?

No public API is recorded for Nordic Bioproducts Group.

What industry is Nordic Bioproducts Group in?

Nordic Bioproducts Group's product category is Specialty Cellulose Excipients. Its primary akta.pro industry code is IMAMALAD, Nanocellulose & Cellulose Derivatives (CNC/CNF, MCC, ethers/esters), with a secondary code of IMAEAOAG, Biodegradable Fibers & Nonwovens (industrial textiles, wipes). Its NAICS code is 3252 and its SIC code is 2820.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Chemical & Engineering NewsTextile recycling tries to gain a second windChemical textile recycling has struggled to reach commercial viability despite early promises in 2022, with major firms like Renewcell filing for bankruptcy, but the sector is now regaining momentum driven by new EU policies mandating separate textile collection and producer responsibility schemes. Nordic companies including Infinited Fiber, Nordic Bioproducts Group, and reborn Circulose are cautiously scaling up operations, while brands like H&M and Inditex are signing supply agreements to secure recycled fiber sources. EU regulations requiring textile producers to cover end-of-life costs took effect in 2025, alongside new ecodesign requirements, creating the policy certainty needed to unlock the estimated 3.9 million metric tons of recycled fiber demand expected by 2030.openPR.comMicrocrystalline Cellulose Powder Manufacturing Plant DPR, Unit Setup & Machinery Cost - 2026IMARC Group published a market report on microcrystalline cellulose (MCC) powder manufacturing, highlighting steady growth driven by pharmaceutical, food, and personal care sectors, with projected gross profit margins of 35-45% and net profit margins of 18-28%. Recent industry developments include Oji Holdings' investment in Nordic Bioproducts Group Oy (January 2026), Roquette's new Health and Pharma Innovation Center in Brazil (October 2025), and Sigachi Industries Limited's Rs.1.5 billion expansion in Gujarat (August 2025). The market benefits from regulatory-driven entry barriers, sustainability advantages of plant-based raw materials, and increasing demand for clean-label ingredients across multiple industries.Wood CentralOji Takes 20% Stake to Turn Paper Fibre into Pharma‑Grade CelluloseOji Holdings has acquired a 20% stake in Finnish biotech company Nordic Bioproducts Group to scale its AaltoCell® technology, which converts paper-grade cellulose into high-purity pharmaceutical ingredients including microcrystalline cellulose (MCC). The partnership targets the US$1.33 billion MCC market, projected to double by 2035, with Nordic Bioproducts operating an EXCiPACT-certified production facility in Lappeenranta, Finland. The investment supports Oji Holdings' strategic shift toward higher-value, sustainable forest-based materials while enabling Nordic Bioproducts Group to expand its technology globally beyond Europe.PulpapernewsOji Holdings makes strategic investment in NBGNordic Bioproducts Group, a Finnish biomaterials company originating from Aalto University, has secured a strategic minority investment from Japan's Oji Holdings Corporation, giving Oji a 20% stake in the company and establishing a long-term partnership for industrial collaboration and global market development of NBG's AaltoCell™ technology. The partnership will initially focus on microcrystalline cellulose, a market currently valued at USD 1.33 billion and projected to double by 2035, with both companies viewing AaltoCell™ as a broader platform technology for producing high-value cellulose-based materials from forest biomass. Nordic Bioproducts Group established its commercial-scale production facility in Lappeenranta, Finland in 2024, and the investment provides capital to accelerate development and international scaling of its specialty cellulose technology.BebeezFinnish Nordic Bioproducts secures strategic investment from Oji to scale cellulose deeptech – BeBeez InternationalEspoo-based biomaterials deeptech Nordic Bioproducts Group has secured a strategic minority investment from Japan's Oji Holdings Corporation, giving Oji a 20% stake in the company, to accelerate the industrial development and global commercialization of its patented AaltoCell™ cellulose platform. The partnership will initially focus on pharmaceutical-grade microcrystalline cellulose (MCC), a market valued at USD 1.33 billion and projected to double by 2035, leveraging Nordic Bioproducts' EXCiPACT-certified production facility in Lappeenranta, Finland. Both companies view the technology as a broader platform for converting forest biomass into higher-value materials, supporting the forest industry's transition beyond traditional pulp and paper.NordicbioproductsJapan’s Oji Holdings Makes Strategic Investment in Finnish Biomaterials Deep Tech Company Nordic Bioproducts GroupJapan's Oji Holdings Corporation has acquired a 20% strategic minority stake in Finnish biomaterials company Nordic Bioproducts Group, establishing a long-term partnership for industrial collaboration and global market development. The investment targets Nordic Bioproducts Group's patented AaltoCell® technology, which produces high-value microcrystalline cellulose (MCC) for pharmaceutical, food, and personal care applications with a reduced environmental footprint compared to conventional methods. Nordic Bioproducts Group, which established a commercial-scale EXCiPACT®-certified production facility in Lappeenranta, Finland in 2024, will use the partnership to accelerate international scaling of its technology from its Finnish base.ArcticstartupFinnish Nordic Bioproducts secures strategic investment from Oji to scale cellulose deeptechEspoo-based Nordic Bioproducts Group has secured a strategic minority investment from Japan's Oji Holdings Corporation, giving Oji a 20% stake in the biomaterials deeptech company. The investment will accelerate the industrial development and global scaling of Nordic Bioproducts' patented AaltoCell™ cellulose platform, starting with pharmaceutical-grade microcrystalline cellulose (MCC), while positioning Finland as the production and development base. The global MCC market is valued at USD 1.33 billion and projected to double by 2035, with both companies viewing AaltoCell™ as a broader platform technology deployable internationally.